Aquestive Therapeutics, Inc. AQST EBITDA

EBITDA at other companies

Indivior Pharmaceuticals, Inc.INDV

$139M+101%

ARS Pharmaceuticals, Inc.SPRY

-$59.75M-61.9%

ViatrisVTRS

$678.6M-25.5%

AMP

Amphastar PharmaceuticalsAMPH

$54.04M-4.9%

AbbVieABBV

$5.93B+2.7%

RegenxbioRGNX

$33.02M+156%

FAQ

What is Aquestive Therapeutics, Inc.'s EBITDA?

Aquestive Therapeutics, Inc. (AQST) reported EBITDA of -$8.09M in Q2 2026.

How has Aquestive Therapeutics, Inc.'s EBITDA changed year-over-year?

Aquestive Therapeutics, Inc.'s EBITDA increased by 28.0% year-over-year, from -$11.23M to -$8.09M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s EBITDA has grown at a 22.1% compound annual growth rate (CAGR), from -$31.72M to -$70.5M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.